Compound Molecular Targets Preclinical Use ClinicalTrials
ABT-737 Bcl-2 and Bcl-Xl(lownM affinity) Multiple myeloma; Acutemyeloid leukemia; Small celllung cancer; Lymphoma Phase I/II
Navitoclax (ABT-263) Bcl-Xl, Bcl-2, Bcl-w,Bcl-B Multiple myeloma; Small celllung cancer; Non-HodgkinLymphoma; Chroniclymphocytic leukemia Phase I/IIa
Venetoclax (ABT-199) Bcl-Xl, Bcl-2, Bcl-w,Bcl-B Multiple myeloma; Small celllung cancer; Chroniclymphocytic leukemia Phase I/II
Obatoclax(GX015-070) Bcl-2, Bcl-Xl, Bcl-w,Mcl-1 Myeloma; Mantle celllymphoma Phase I/II
Gossypol (BL -193, AT-101) Mcl-1, Bcl-2, Bcl-Xl Head and neck tumors; Malignant gliomas Phase II/III
Apogossypolone(ApoG2) Bcl-2, Mcl-1, Bcl-Xl(highest to lowestaffinity) Non-Hodgkins Lymphoma,Lymphoma Preclinical
TW-37 Bcl-w, Bcl-Xl, A1,Mcl-1, Bcl-2 Non-Hodgkins Lymphoma,Pancreatic, Lung Preclinical
Tetrocarcin A Bcl-2 and Bcl-Xl Leukemia and others Preclinical
Table 1: List of BCL-2 family inhibitors.